Journal article

Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor-Negative Breast Cancer Survival

Elizabeth M Azzato, Jonathan Tyrer, Peter A Fasching, Matthias W Beckmann, Arif B Ekici, Ruediger Schulz-Wendtland, Stig E Bojesen, Borge G Nordestgaard, Henrik Flyger, Roger L Milne, Jose Ignacio Arias, Primitiva Menendez, Javier Benitez, Jenny Chang-Claude, Rebecca Hein, Shan Wang-Gohrke, Heli Nevanlinna, Tuomas Heikkinen, Kristiina Aittomaki, Carl Blomqvist Show all



BACKGROUND: Traditional prognostic factors for survival and treatment response of patients with breast cancer do not fully account for observed survival variation. We used available genotype data from a previously conducted two-stage, breast cancer susceptibility genome-wide association study (ie, Studies of Epidemiology and Risk factors in Cancer Heredity [SEARCH]) to investigate associations between variation in germline DNA and overall survival. METHODS: We evaluated possible associations between overall survival after a breast cancer diagnosis and 10 621 germline single-nucleotide polymorphisms (SNPs) from up to 3761 patients with invasive breast cancer (including 647 deaths and 26 978 p..

View full abstract


Awarded by Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario

Awarded by Deutsche Krebshilfe e.V.

Awarded by Academy of Finland

Awarded by National Breast Cancer Foundation and the National Health and Medical Research Council (NHMRC)

Awarded by NIH

Awarded by NIH, National Cancer Institute

Awarded by Lon V. Smith Foundation

Awarded by Cancer Research UK

Awarded by The Francis Crick Institute


Funding Acknowledgements

Cancer Research UK (C1287 and A7497 to D. F. E.). E. M. A. is supported by the National Cancer Institute and the National Institutes of Health (NIH)-Cambridge Graduate Partnership Program. Bavarian Breast Cancer Cases and Controls (BBCC) was supported by the ELAN Fonds of the University of Erlangen, and P. A. F. is funded by Dr Mildred Scheel Stiftung and Deutsche Krebshilfe e.V. CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Copenhagen University Hospital, Herlev Hospital. Spanish National Cancer Centre Breast Cancer Study (CNIO-BCS) was supported by the Genome Spain Foundation, the Red Tematica de Investigacion Cooperativa en Cancer, and grants from the Asociacion Espanola Contra el Cancer and the Fondo de Investigacion Sanitario (PI081120 to J. Ben., PI081583 to R. L. M.]. Genetic Epidemiology Study of Breast Cancer by Age 50 (GESBC) was supported by the Deutsche Krebshilfe e. V. (70492) and GESBC genotyping in part by the state of Baden-Wurttemberg through the Medical Faculty of the University of Ulm (P. 685). Helsinki Breast Cancer Study (HEBCS) has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (110663), the Finnish Cancer Society, and the Sigrid Juselius Foundation. Kuopio Breast Cancer Project (KBCP) is supported by grants from erityisvaltionosuus (EVO) funds of Kuopio University Hospital, EVO funds of Vaasa Central Hospital, the Finnish Cancer Foundation, and the Academy of Finland. The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer is supported by grants from the National Breast Cancer Foundation and the National Health and Medical Research Council (NHMRC) (145684, 288704, and 454508) and by the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; and the Cancer Foundation of Western Australia. Mayo Clinic Breast Cancer Study (MCBCS) was supported by grants from the NIH (P50 CA116201 and R01 CA122340). Melbourne Collaborative Cohort Study (MCCS) was supported by NHMRC (209057, 251533, 396414, and 504711). Infrastructure support for the MCCS recruitment and follow-up is provided by the Cancer Council Victoria, whereas cohort recruitment was partly funded by VicHealth. Genotyping was in part supported by the Prostate Cancer Foundation of Australia. Leiden University Medical Centre Breast Cancer Study (ORIGO) was supported by the Dutch Cancer Society. Polish Breast Cancer Study was funded by intramural research funds of the National Cancer Institute, Department of Health and Human Services. SASBAC was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US NIH, and the Susan G. Komen Breast Cancer Foundation. Sheffield Breast Cancer Study (SBCS) was supported by Yorkshire Cancer Research and the Breast Cancer Campaign. University of California Irvine Breast Cancer Study (UCIBCS) is supported by the NIH, National Cancer Institute (CA-58860), and the Lon V. Smith Foundation (LVS-18840).